Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional Profile Tumor Evolution in Metastatic and Non Metastatic MYC driven HCC

ABSTRACT: Comparative transcriptional profiling of MYC driven HCC and MYC/Twist1 driven HCC during tumor progression, regression and recurrence.

ORGANISM(S): Mus musculus

PROVIDER: GSE243176 | GEO | 2024/08/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity

Project description:Comparative transcriptional profiling of MYC driven HCC and MYC/Twist1 driven HCC during tumor progression, regression and recurrence.

2020-01-21 | GSE135878 | GEO

MYC-driven mouse HCC proteomics

Project description:To identify proteomic signatures associated with hepatocellular carcinoma driven by MYC overexpression, proteomics was performed on the LAP-tTA/tetO-MYC mouse conditional liver cancer model. Upon MYC activation, mice form liver cancer. Differential proteomics was performed in "MYC on" (MYC-HCC) mouse liver tumors versus mouse control normal liver tissue (where MYC was not overexpressed to drive tumorigenesis -- "MYC off").

2022-10-12 | PXD031478 | Pride

Transcriptional Profile Tumor Evolution in Metastatic and Non Metastatic MYC driven HCC

Project description:Transcriptional Profile Tumor Evolution in Metastatic and Non Metastatic MYC driven HCC

| PRJNA1016481 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vivo]

Project description:Transgenic MYC/Twist1 HCC uncergoes tumor regression with persistence of minimal residaul disease (MRD) in the liver upon oncogene deprivation.

2024-08-06 | GSE242743 | GEO

MYC-HCC treated with immunotherapy

Project description:MYC-HCC treated with immunotherapy

| PRJNA888064 | ENA

MYC-HCC treated with immunotherapy

Project description:Murine MYC-HCC were treated with control IgG or anti PDL1 or anti CTLA4, or their combination. Tumors were sequenced using Nanostring IO360.

2023-02-01 | GSE215006 | GEO

CRISPR/Cas9 genome-wide screen and transcriptome profiling in a MYC-conditional HCC model [CRISPR]

Project description:The MYC oncogene is often dysregulated in human cancer, including hepatocellular carcinoma (HCC). However, MYC is considered undruggable to date. Here, we comprehensively identify genes essential for the survival of MYC-high but not MYC-low cells by performing a CRISPR/Cas9 genome-wide screen in a MYC-conditional HCC model. Our screen identifies novel MYC-synthetic lethal interactions, as well as most previously identified MYC-synthetic lethal genes. In particular, we found genes involved in nuclear to cytoplasmic transport to be MYC-synthetic lethal in HCC, and we show that many of these genes are transcriptionally upregulated in MYC-high murine HCC.

2023-10-30 | GSE205131 | GEO

CRISPR/Cas9 genome-wide screen and transcriptome profiling in a MYC-conditional HCC model [RNA-seq]

2023-10-30 | GSE205130 | GEO

TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway [RNA-Seq]

Project description:Hepatocellular carcinoma (HCC) is a formidable malignancy with limited effective therapeutic avenues. This study was designed to investigate the role of transglutaminase 2 (TGM2) in promoting HCC progression and assess its potential as a target for therapeutic intervention in HCC treatment.TMG2 expression was positively related to a higher AFP level, poor differentiation, and a later BCLC stage. Tgm2 deficiency or H3Q5ser inhibition notably restrained HCC progression. Mechanism research revealed that TGM2-mediated H3Q5ser modifications promote HCC progression via MYC pathway signaling. Furthermore, transcriptional intermediary factor 1 beta (TIF1-β/TRIM28) mediated the recruitment of TGM2 by MYC to facilitate H3Q5ser modifications on MYC targets. Finally, targeting the TGM2 transglutaminase activity significantly suppressed HCC progression in preclinical models.

2024-12-16 | GSE283279 | GEO

TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway [Cut & Tag]

2024-12-16 | GSE283278 | GEO